Navigation Links
Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder
Date:1/8/2009

Current and Emerging Drugs Will Not Surpass Vyvanse as the Clinical Gold Standard, According to a New Report From Decision Resources

WALTHAM, Mass., Jan. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that physicians indicate there is an unmet need for a safe and effective nonstimulant therapy approved for adult attention-deficit/hyperactivity disorder (ADHD) with no risk of suicidal ideation. Such a drug has potential to earn a 25 percent patient share of the drug treated adult ADHD population, according to surveyed U.S. psychiatrists. In contrast, in Europe, such an agent would earn a markedly higher patient share of 40 percent, according to surveyed European psychiatrists.

This difference in patient share likely reflects U.S. physicians' reasonably high level of satisfaction with currently-available psychostimulants, with which they have decades of clinical experience, despite their disadvantages of abuse-liability and prescribing restrictions. Conversely, European physicians have to contend with greater prescribing restrictions, fewer treatment options, and are more averse to stimulants' risk of abuse than their U.S. counterparts. As a result, physicians would greatly welcome a safer and more effective nonstimulant alternative to Eli Lilly's Strattera as a first-line therapy for adult ADHD.

The new report entitled Attention-Deficit/Hyperactivity Disorder: Emerging Therapies Fall Short of Physicians' Expectations for Safer and More-Effective Nonstimulants finds that current and emerging drugs have not yet demonstrated substantial clinical advantages over Shire's Vyvanse, Decision Resources' 2008 clinical gold standard in the treatment of ADHD. According to interviewed physicians, none of the emerging therapies represent a major innovation in ADHD treatment or offer an overwhelmingly prefera
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Renal Physicians Association 2009 Annual Meeting
2. Medical Specialists of the Palm Beaches Selects Allscripts Electronic Health Record to Connect and Automate 85 Physicians
3. The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians
4. Aurora Physicians Receive National Recognition for Quality Diabetes Care
5. Stem Cells Poised to Grow Organs for Transplant : Zannos Grekos, MD Presents Clinical Data of Research with Adult Stem Cells to Physicians at International Regenerative Biomedicine Conference
6. Supply of board-certified emergency physicians unlikely to meet projected needs
7. Dr. Steven Liu, Founder of Ingenious Med, Recognized as a Leading Hospitalist by the American College of Physicians
8. The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians
9. Medscape Physician Connect Becomes Largest Online Physician Social Network with More than 100,000 Physicians
10. Scientists, Physicians, Health, and Environmental Justice Advocates to New Obama EPA Director: We Look Forward to Toxic Chemical Regulatory Reform
11. Anti-Aging Miracle Physicians Have Been Waiting for is Finally Here : Free Book Available From Natural Health News Report Reveals the Secret to Staying Young
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... (PRWEB) July 22, 2014 DocbookMD ... process of deploying one of the largest physician-centric mobile ... ( MHMD ) in Houston. , Created by Austin-based ... the DocbookMD application will be embedded into MHMD’s Accountable ... searched for the best technology to put this capability ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Dr. Dental is ... existing patients and new visitors in mind, one of the ... and visual layout that makes navigation very easy. Dr. Dental ... experience of going to the dentist affordable, convenient and fun, ... helpful new feature is an appointment scheduling system right on ...
(Date:7/22/2014)... 22, 2014 A Florida woman has ... that alleges the death of her husband was the ... thinner, Bernstein Liebhard LLP reports. According to her complaint, ... for the Southern District of Florida on June 23rd, ... suffered a subdural hemorrhage the following June. Despite emergency ...
(Date:7/22/2014)... Among women undergoing a minimally invasive hysterectomy using electric ... 10,000 women at the time of the procedure, according ... has been concern that this procedure, in which the ... the spread of undetected malignancies. , Despite the commercial ... estimates of the prevalence of malignancy at the time ...
(Date:7/22/2014)... July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014”) championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). , ...
Breaking Medicine News(10 mins):Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 2Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 3Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 4Health News:Dr. Dental Reveals Exciting New Website 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2
... , , BETHESDA, Md., Nov. 16 ... appointment of Michele Perry as chief operating officer. Ms. Perry, ... the company to a new level of growth and deliver ... Interactive Patient Care solution. Among her priorities, Ms. Perry ...
... Experts unsure if growth stems from more awareness or actual ... Pediatric food allergies, which can sometimes be life-threatening, are increasing ... shows. , But the study authors aren,t sure if the ... actual prevalence or if better awareness has led more people ...
... , SINGAPORE, Nov. 16 ... of Malaysia grew steadily in the first half of 2009 ... and,aggressive promotions from major Contact Lens manufacturers. Positive sales,data showing ... cemented,the view of an economic recovery that is being led ...
... ... Interactive Regulatory Compliance Training Provides Critical Strategies for Successful Interactions Between Life Science ... ... Stimaré , a specialized sales enablement and IT consulting company, today announced ...
... ... Wear Ankle-Foot Orthoses (AFOs) , ... Westchester, NY (PRWEB) November 16, 2009 -- Ross Daniel Adaptive Apparel (RDAA), a ... launch of “Cool Clothes for Toes,” the first creatively styled sock line for children and ...
... NANJING, China, Nov. 16 /PRNewswire-Asia/ -- Simcere ... leading pharmaceutical company,specializing in the development, manufacturing, and marketing of branded,generic ... quarter ended September 30, 2009. , , Highlights, ... for the third, quarter of ...
Cached Medicine News:Health News:GetWellNetwork Taps High-Tech Veteran Michele Perry as Chief Operating Officer 2Health News:Child Food Allergies on the Rise in U.S. 2Health News:Child Food Allergies on the Rise in U.S. 3Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 3Health News:Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 12
(Date:7/22/2014)... , July 22, 2014  Pressure ... "Company") and Parabase Genomics ("Parabase"), (together "the ... a strategic research and development agreement (the ... PBI will develop a front-end, sample preparation ... and newborn confirmatory testing process. The sample ...
(Date:7/22/2014)... July 22, 2014  NeuroSigma, Inc. (NeuroSigma), a ... commercialization of its non-invasive Monarch ™ eTNS™ ... disorders, today announced that enrollment has begun in a ... (eTNS) as adjunctive therapy for the treatment of Lennox-Gastaut ... at the Olive View-UCLA Medical Center in ...
(Date:7/22/2014)... , July 22, 2014 ... umfassenden Schutz von Pharmazeuten und Krankenpflegern ... Equashield ( http://www.equashield.com ), ... System Transfer Devices, CSTDs) für gefährliche Medikamente, ernannte ... und Hersteller von medizinischen Produkten, zu seinem ...
Breaking Medicine Technology:Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... Turn the Tide on Antibiotic-Resistant InfectionsPRINCETON, N.J., March ... and the Plexus Institute (Plexus) today announce results ... Staphylococcus aureus (MRSA) prevention program that employed ... and behavioral change, to trigger significant reductions in ...
... the "NEXT" Study Also Showed Arzoxifene Significantly Suppressed ... with OsteoporosisATHENS, Greece, March 23 Eli Lilly ... new data showing arzoxifene, an investigational selective estrogen ... increasing bone mineral density (BMD) in the lumbar ...
Cached Medicine Technology:CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 2CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 3CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 2Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 3Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: